Tomasz Ciach PhD Eng. Professor
 
Beata Butruk-Raszeja PhD Eng.
 
Magdalena Janczewska MSc Eng.
 
Katarzyna Każmierska MSc Eng.
Kamil Kopeć MSc Eng.
 
Piotr Kowalczyk MSc Eng.
 
Martyna Kucharska PhD Eng.
 
Aleksandra Kuźmińska, MSc Eng.
 
Aleksandra Kulikowska MSc Eng.
 
Ilona Łojszczyk MSc Eng.
 
Aleksandra Mościcka-Studzińska MSc Eng.
 
Rafał Podgórski MSc Eng.
 
Aleksandra Poniatowska MSc Eng.
 
Agata Stefanek MSc Eng.
 
Paulina Trzaskowska MSc Eng.
 
Maciej Trzaskowski MSc Eng.
 

Iga Wasiak MSc Eng.

 
Michał Wojasiński MSc Eng.
 

 

Home arrow Projects arrow Microparticles in medicine and pharmacy arrow Application and production of microparticles
Application and production of microparticles
Microparticles are small beads with the potentially very broad application in medicine and pharmacy. Depends of the use they may be solid, porous or empty inside. They are made from drug, biocompatible polymer or their mixture. The size of such particles is within the range of 1-500 μm, but it is necessary to narrow the diameter distribution taking into account the requirements of a definite use. For specific applications are also manufactured nanoscale particles, which diameter is less than 100 nm.
Microparticles can be the base for working out a system for drug administration. The active substance is controlled released from the matrix of such beads by way of diffusion and during the simultaneously degradation of the matrix, in the case of biodegradable materials application. Microparticles may be administrated to the patient's body through by routs. In oral forms they may be a filling of capsules and intestinal tablets. They are also used as a powder for inhalation. Often are used for creating implantable therapeutic systems, it means that drug loaded beads made of biodegradable material are immobilized in tissue (such as muscle or under the skin). This route of administration allows both local and systemic therapy. The slow drug releasing, e.g. during several weeks, makes enable decreases pharmacotherapy difficulty - patients don’t have to remember about their daily dose of medicine. In the case of microparticles with a range of diameter smaller than the capillaries diameter and administrated intravenously it is possible to develop a form of targeted therapy, what means that the drug reaches selectively only to specific cells. This is achieved by modifying the composition of the surface of particles so that they will be accumulating only in an area of tissue cancer or inflammatory.
Besides to pharmacotherapy microparticles may have other applications in medicine. A hollow ones, so-called microbubbles with precisely chosen diameter and made from biodegradable material may be applied for embolization (blocking) the blood vessels feeding nutrients to cancer tumor. This is less invasive treatment which ensures the reduction of tumor. Microbubbles also serve as a contrast media in medical ultrasonography - their suspension injected to the blood vessels improve the signal.

There are many methods of microparticles manufacture, and the choice of technology should depend on the requirements for particle size, morphology and acceptable range of the diameters as well as the efficiency of the process. The simplest classification of these techniques can be based on the phase type, where take place the forming of particles: gas phase or the liquid phase. The first group included different version of spray drying and electrohydrodynamic atomization (EHDA), the second group includeed the polymerization or chemical modification carried out in solution and the evaporation of solvent from emulsions. In BioMedical Engineering Laboratory we obtain microparticles by means of all these techniques, but many of them are conducted in own designed apparatus. We use the following biodegradable polymers for microparticles production: polycaprolactone (PCL), polylactide acid (PLA), and chitosan. Creating forms for releasing of both lipophilic and hydrophilic drugs. For example we worked out PCL microparticles with a diameter of 100 +-10 μm for 14 days long releasing a drug for central nervous system degenerative diseases. In addition, we have own method for testing in vitro active substance release profile from these extremely small drug forms.

 

 
< Prev   Next >